Serina Therapeutics Inc (SER) Actualités

Form 8-K - Current report

Serina Therapeutics to Present at the 14th Annual Injectables Summit

HUNTSVILLE, AL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

HUNTSVILLE, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a...

Form 8-K - Current report

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

HUNTSVILLE, July 29, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a...

Form 8-K - Current report

Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation

HUNTSVILLE, AL, July 18, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER...

Form 4 - Statement of changes in beneficial ownership of securities